Mr Mrs Miss Ms Dr Other

Miss
Ruby
Mullens

Trainee Patent Attorney

London Office

Life sciences

Telephone. +44(0) 161 247 4900
Email. rmullens@hgf.com
Vcard
Linkedin

Experience

Ruby graduated in 2023 with a first class Master's degree in Biochemistry from the University of Oxford, where she was awarded scholarships and academic prizes in recognition of her performance. She since joined HGF in January 2025 as a Trainee Patent Attorney in the Life Science team.

She has a broad technical background, having studied genetics, molecular & cellular biology, metabolic processes, macromolecular structures, drug design, chemical pharmacology, bacterial warfare, antibiotic resistance, and biochemical methods.

During her Master's, Ruby conducted a research project in Neurobiology at the Szele Lab, University of Oxford. Here she explored the role of tumour-associated lncRNAs in neural migration using a range of in-vitro and in-vivo gene editing techniques. In the same year, she completed a comprehensive review of β2-adrenoreceptor signaling in skeletal muscle, offering insights into its therapeutic potential for glucometabolic regulation in type 2 diabetes.

Ruby's particular interests and expertise lie in human metabolism, cellular signaling, cancer biology, and disease pathogenesis at the molecular and cellular level.

Specialisms

Industries

Services

Qualifications

Trainee

MBIOCHEM

MBiochem in Molecular and Cellular Biochemistry, University of Oxford (First Class Honours)

OTHER

Supplemental Subject in Chemical Pharmacology (Distinction)

Recognition

Nuffield Scholarship in Biochemistry, St Hilda's College, University of Oxford

Porter Prize for Performance, Department of Biochemistry, University of Oxford

Proxime Accessit Gibbs Prize for Performance, Department of Biochemistry, University of Oxford

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Often Copied, Never Equaled: When Do Everyday Items Become Subject of Copyright?

The  borderline between ‘pure’ works of art and mere utilitarian objects” –  Can iconic, yet everyday products be protected under copyright? The above question was posed by Advocate General in …

Read article

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us